Epidemiology


Etiology


Pathophysiology

  • Point mutation in the β-globin gene (chromosome 11) → glutamic acid replaced with valine (single amino acid substitution) → 2 α-globin and 2 mutated β-globin subunits create pathological hemoglobin S (HbS).
    • Heterozygotes (HbAS): carry one sickle allele and one other (usually normal) → sickle cell trait
    • Homozygotes (HbSS): carry two sickle alleles → sickle cell anemia
  • HbS polymerizes when deoxygenated, causing deformation of erythrocytes (“sickling”). This can be triggered by any event associated with reduced oxygen tension.
    • Hypoxia (e.g., at high altitudes)
      • In homozygotes, up to 100% of the hemoglobin molecules are affected, leading to sickle cell formation under minimally decreased oxygen tension.
      • In heterozygotes, sickling only occurs due to severe reduction in oxygen tension.
    • Infections
    • Dehydration
    • Acidosis
    • Sudden changes in temperature
    • Stress
  • Sickle cells lack elasticity and adhere to vascular endothelium, which disrupts microcirculation and causes vascular occlusion and subsequent tissue infarction.
  • Hemolysis and the subsequent increased turnover of erythrocytes may increase the demand for folate, causing folate deficiency.
    • Can present as macrocytic anemia
  • Extravascular hemolysis and intravascular hemolysis are common and result in anemia.

Clinical features


Diagnostics

  • Normal RBC indices (e.g. MCV)
    • Not all red blood cells are sickled

Treatment

Overview

Infants and children

  • Antibiotic prophylaxis against invasive pneumococcal disease until 5 years of age
  • Hydroxyurea therapy regardless of clinical severity to minimize disease-related complications (First-line)
  • Annual transcranial doppler to screen for stroke risk from 2 months till 16 years of age

Hydroxyurea therapy

Indications

  • All infants > 9 months, children, and adolescents with sickle cell anemia regardless of symptom severity
  • Adults with any of the following:
    • Frequent (≥ 3 episodes/year) acute pain episodes or other vasoocclusive events
    • Severe symptomatic anemia
    • History of severe and/or recurrent acute chest syndrome

Mechanism of action

Stimulation of erythropoiesis and increased fetal hemoglobin


Complications

Splenic sequestration

  • Pathophysiology: splenic vasoocclusion and entrapment and pooling of large amounts of blood in the spleen
  • Clinical presentation
    • Most commonly affects children < 5 years of age
    • Acute left upper quadrant pain, splenomegaly
    • Hypotension and/or hypovolemic shock, especially in infants
      • Due to the trapping of blood in the spleen
    • Symptoms of anemia (e.g., pallor, fatigue)
    • Functional asplenia: Increased risk of infection with encapsulated bacteria (Streptococcus pneumoniae (most common), Neisseria meningitis, Haemophilus influenzae type b
  • Supportive findings
    • Anemia (Hb drop of ≥ 2 g/dL) with reticulocytosis
    • Thrombocytopenia
  • Acute management
    • Immediate IV fluid resuscitation for hypovolemia
    • Simple RBC transfusion in consultation with a sickle cell expert (avoid raising hemoglobin > 8 g/dL)